



The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Zyla Life Sciences is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 4.4% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	55,126
Cost of Goods Sold	0
Intangible Assets	184
Liabilities, Current	7,429
Liabilities, Non-Current	0
Other Assets	843
Other Compr. Net Income	-1,296
Other Expenses	47
Other Liabilities	8,880
Other Net Income	-6,031
Other Revenues	1,920
Property and Equipment	4,417
Research and Development	22,395
Selling, General and Administrative Expense	16,661

Output Variable	Value in 1000 USD
Assets	60,570
Liabilities	16,309
Expenses	39,103
Revenues	1,920
Stockholders Equity	44,261
Net Income	-43,214
Comprehensive Net Income	-43,862
BaseVar	62,614
ECR before LimitedLiability	137%
Economic Capital Ratio	258%